(Q38084442)

28 August 2017

Beyond the clinic: 'direct-to-consumer' genomic profiling services and pharmacogenomics (English)

1 reference

28 August 2017

1 reference

1

Barbara Prainsack

0 references

Effy Vayena

series ordinal

2

object named as

Effy Vayena

1 reference

28 August 2017

1 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

14

1 reference

28 August 2017

4

1 reference

28 August 2017

403-412

1 reference

Concordance study of 3 direct-to-consumer genetic-testing services

28 August 2017

1 reference

Web-based, participant-driven studies yield novel genetic associations for common traits

21 January 2018

1 reference

Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease

21 January 2018

1 reference

Efficient replication of over 180 genetic associations with self-reported medical data

21 January 2018

1 reference

Letting the genome out of the bottle--will we get our wish?

21 January 2018

1 reference

Direct-to-consumer genetic testing: perceptions, problems, and policy responses

21 January 2018

1 reference

The evidence dilemma in genomic medicine.

21 January 2018

1 reference

Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic

21 January 2018

1 reference

The general public's understanding and perception of direct-to-consumer genetic test results.

21 January 2018

1 reference

ASHG Statement* on Direct-to-Consumer Genetic Testing in the United States

21 January 2018

1 reference

Evaluating the utility of personal genomic information

21 January 2018

1 reference

Health care providers and direct-to-consumer access and advertising of genetic testing in the United States

21 January 2018

1 reference

Legislation on direct-to-consumer genetic testing in seven European countries

21 January 2018

1 reference

Genetic testing legislation in Western Europe-a fluctuating regulatory target.

21 January 2018

1 reference

Research 2.0: social networking and direct-to-consumer (DTC) genomics

21 January 2018

1 reference

Personalized genomic medicine and the rhetoric of empowerment

21 January 2018

1 reference

Is there a doctor in the house? : The presence of physicians in the direct-to-consumer genetic testing context

21 January 2018

1 reference

To ban or not to ban? Clinical geneticists' views on the regulation of direct-to-consumer genetic testing

21 January 2018

1 reference

Consumers' views of direct-to-consumer genetic information

21 January 2018

1 reference

Personal genomics and individual identities: motivations and moral imperatives of early users

21 January 2018

1 reference

Experiences of early users of direct-to-consumer genomics in Switzerland: an exploratory study

21 January 2018

1 reference

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics

21 January 2018

1 reference

Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others

21 January 2018

1 reference

Personal genomics services: whose genomes?

21 January 2018

1 reference

Personalized participatory medicine: sharing knowledge and uncertainty

21 January 2018

1 reference

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

21 January 2018

1 reference

National surveillance of emergency department visits for outpatient adverse drug events

21 January 2018

1 reference

Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults

21 January 2018

1 reference

On rat poison and human medicines: personalizing warfarin therapy

21 January 2018

1 reference

Overcoming regulatory and economic challenges facing pharmacogenomics

21 January 2018

1 reference

Pharmacogenomics in clinical practice and drug development

21 January 2018

1 reference

Three arguments against prescription requirements

21 January 2018

1 reference

Pharmacogenetics education in British medical schools

21 January 2018

1 reference

Pharmacogenetics education: 10 years of experience at Tel Aviv University.

21 January 2018

1 reference

Reforming Pharmaceutical Education to Enhance the Global Uptake of Pharmacogenomics and Personalized Medicine

21 January 2018

1 reference

Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey

21 January 2018

1 reference

Primary care physicians' knowledge of and experience with pharmacogenetic testing

21 January 2018

1 reference

Survey of US public attitudes toward pharmacogenetic testing

21 January 2018

1 reference

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

Direct-to-consumer pharmacogenomic testing

21 January 2018

1 reference

21 January 2018

Misdirected precaution

1 reference

Direct-to-Consumer Genetic Testing

21 January 2018

1 reference

Direct-To-Consumer Genetics and Health Policy: A Worst-Case Scenario?

21 January 2018

1 reference

Pharmacogenomic Testing: Knowing More, Doing Better

21 January 2018

1 reference

Next-generation DNA sequencing, regulation, and the limits of paternalism: the next challenge

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.13.10

1 reference

28 August 2017

1 reference

PubMed ID

23438887